

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

INSIDE INFORMATION AND RESUMPTION OF TRADING

Reference is made to the announcement of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 18 September 2020 in relation to the trading halt of the Company’s shares (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pending the release of an announcement in relation to inside information of the Company.

This announcement is made by the board of directors (the “**Board**”) of the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 17 September 2020, the Company learned that the Customs Anti-Smuggling Department (the “**Authority**”) of the People’s Republic of China (“**PRC**”) inspected the Group’s places of business in Nanjing and Zhenjiang, China. The inspections are in connection with what the Company understands to be an investigation (the “**Investigation**”) relating to suspected violations of import and export regulations under the laws of the PRC.

In connection with the Investigation, Dr. Fangliang Zhang, our chairman, non-executive Director, and one of our controlling shareholders, is presently under “residential surveillance”¹ (“**監視居住**”) in the PRC. At the time of this announcement, to the Company’s knowledge, four other employees of the Group were detained for questioning. The Authority has not provided any document indicating that the residential surveillance of Dr. Zhang relates to his role as an officer or director of the Company or any of its subsidiaries.

¹ According to the Criminal Procedure Law of the PRC (中華人民共和國刑事訴訟法), residential surveillance is a measure by the law enforcement agencies to restrict a suspect from leaving his residence or designated residence within a specified period of time, monitor his behavior and restrict his personal freedom.

As at the time of this announcement, to the Company's knowledge, no charges have been filed against any entity or individual.

In spite of the above, Dr. Zhang may continue to take part in decision makings of the Group's major matters via appropriate means, and as a non-executive Director of the Company, he does not participate in the daily operation of the Company.

Dr. Zhang is currently the chairman and Chief Executive Officer of Legend Biotech Corporation ("**Legend Biotech**"), being one of the Company's subsidiaries. In light of the current restrictions on Dr. Zhang, the board of directors of Legend Biotech has appointed Dr. Ying Huang, currently Legend Biotech's Chief Financial Officer, to serve as the interim Chief Executive Officer, effective as of 21 September 2020. Dr. Huang will continue to hold his position of Legend Biotech's Chief Financial Officer.

There have been no other details released by the Authority as of the date of this announcement.

As at the date of this announcement, the Group's business operations remain normal.

The Company has taken legal advice as appropriate. The Company will monitor this matter and will proactively assist the law enforcement authority with the Investigation, if required. The Investigation is still ongoing. The Company will make public announcement in a timely manner on any important development of the Investigation.

RESUMPTION OF TRADING

At the request of the Company, trading of shares of the Company was halted with effect from 9:00 a.m. on Friday, 18 September 2020. Application has been made by the Company to the Stock Exchange for the resumption of trading of the Shares of the Company with effect from 9:00 a.m. on Tuesday, 22 September 2020.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Wang Ye
Executive Director

Hong Kong, 21 September 2020

As at the date of this announcement, the executive Directors are Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.

* *For identification purposes only*